|
SI3590928T1
(sl)
|
2011-04-08 |
2021-10-29 |
Janssen Sciences Ireland Unlimited Co |
Derivati pirimidina za zdravljenje virusnih okužb
|
|
EA036645B1
(ru)
|
2011-11-09 |
2020-12-03 |
Янссен Сайенсиз Айрлэнд Юси |
Производные пурина для лечения вирусных инфекций
|
|
EP2812331B1
(de)
|
2012-02-08 |
2019-01-02 |
Janssen Sciences Ireland Unlimited Company |
Piperidinopyrimidinderivate zur behandlung von virusinfektionen
|
|
MY167797A
(en)
|
2012-07-13 |
2018-09-26 |
Janssen Sciences Ireland Uc |
Macrocyclic purines for the treatment of viral infections
|
|
EP2906563B1
(de)
|
2012-10-10 |
2018-02-28 |
Janssen Sciences Ireland UC |
Pyrrolo[3,2-d]pyrimidin-derivate zur behandlung von virusinfektionen und anderen erkrankungen
|
|
AU2013346793B2
(en)
|
2012-11-16 |
2018-03-08 |
Janssen Sciences Ireland Uc |
Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
|
|
KR102300861B1
(ko)
|
2013-02-21 |
2021-09-10 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염의 치료를 위한 2-아미노피리미딘 유도체
|
|
HRP20170654T1
(hr)
|
2013-03-29 |
2017-06-30 |
Janssen Sciences Ireland Uc |
Makrociklički deaza-purinoni za liječenje virusnih infekcija
|
|
WO2014187932A1
(en)
|
2013-05-24 |
2014-11-27 |
Janssen R&D Ireland |
Pyridone derivatives for the treatment of viral infections and further diseases
|
|
CA2913028C
(en)
|
2013-06-27 |
2022-03-08 |
Janssen Sciences Ireland Uc |
Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
|
|
JP6401788B2
(ja)
|
2013-07-30 |
2018-10-10 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
ウイルス感染治療用チエノ［３，２−ｄ］ピリミジン誘導体
|
|
CU20180011A7
(es)
|
2015-03-04 |
2018-06-05 |
Gilead Sciences Inc |
Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll
|
|
CA2995004A1
(en)
|
2015-08-26 |
2017-03-02 |
Gilead Sciences, Inc. |
Deuterated toll-like receptor modulators
|
|
WO2017048727A1
(en)
|
2015-09-15 |
2017-03-23 |
Gilead Sciences, Inc. |
Modulators of toll-like recptors for the treatment of hiv
|
|
HUE056243T2
(hu)
|
2015-12-15 |
2022-02-28 |
Gilead Sciences Inc |
Emberi immunhiányt okozó vírust semlegesítõ ellenanyagok
|
|
KR102202984B1
(ko)
|
2016-05-27 |
2021-01-13 |
길리애드 사이언시즈, 인코포레이티드 |
Ns5a, ns5b 또는 ns3 억제제를 사용하여 b형 간염 바이러스 감염을 치료하는 방법
|
|
BR102017010009A2
(pt)
|
2016-05-27 |
2017-12-12 |
Gilead Sciences, Inc. |
Compounds for the treatment of hepatitis b virus infection
|
|
WO2018002319A1
(en)
*
|
2016-07-01 |
2018-01-04 |
Janssen Sciences Ireland Uc |
Dihydropyranopyrimidines for the treatment of viral infections
|
|
JOP20190024A1
(ar)
|
2016-08-26 |
2019-02-19 |
Gilead Sciences Inc |
مركبات بيروليزين بها استبدال واستخداماتها
|
|
US10640499B2
(en)
|
2016-09-02 |
2020-05-05 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
|
PL3507276T3
(pl)
*
|
2016-09-02 |
2022-02-21 |
Gilead Sciences, Inc. |
Związki modulatory receptorów toll-podobnych
|
|
RU2759678C2
(ru)
*
|
2016-09-09 |
2021-11-16 |
Новартис Аг |
Соединения и композиции в качестве ингибиторов эндосомальных toll-подобных рецепторов
|
|
US10968184B2
(en)
|
2016-09-29 |
2021-04-06 |
Janssen Sciences Ireland Unlimited Company |
Pyrimidine prodrugs for the treatment of viral infections and further diseases
|
|
DK3526323T5
(da)
|
2016-10-14 |
2024-09-02 |
Prec Biosciences Inc |
Modificerede meganucleaser der er specifikke for en genkendelsessekvens i hepatitis b virusgenomet
|
|
TW202510891A
(zh)
|
2017-01-31 |
2025-03-16 |
美商基利科學股份有限公司 |
替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
|
|
UY37581A
(es)
|
2017-02-02 |
2018-08-31 |
Gilead Sciences Inc |
Compuestos para el tratamiento de la infección por virus de la hepatitis b
|
|
BR102018007822A2
(pt)
|
2017-04-20 |
2018-11-06 |
Gilead Sciences, Inc. |
composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
|
|
TW202024061A
(zh)
|
2017-08-17 |
2020-07-01 |
美商基利科學股份有限公司 |
Hiv蛋白質膜抑制劑之固體形式
|
|
AR112412A1
(es)
|
2017-08-17 |
2019-10-23 |
Gilead Sciences Inc |
Formas de sal de colina de un inhibidor de la cápside del vih
|
|
EP3672970A1
(de)
|
2017-08-22 |
2020-07-01 |
Gilead Sciences, Inc. |
Therapeutische heterocyclische verbindungen
|
|
TW201915000A
(zh)
*
|
2017-09-22 |
2019-04-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合雜芳基衍生物、其製備方法及其在醫藥上的應用
|
|
WO2019084060A1
(en)
|
2017-10-24 |
2019-05-02 |
Silverback Therapeutics, Inc. |
CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
|
|
JP2021506827A
(ja)
|
2017-12-15 |
2021-02-22 |
シルバーバック セラピューティックス インコーポレイテッド |
肝炎の治療用の抗体コンストラクト−薬物コンジュゲート
|
|
US11203610B2
(en)
|
2017-12-20 |
2021-12-21 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
US10966999B2
(en)
|
2017-12-20 |
2021-04-06 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
|
|
AU2019222644B2
(en)
|
2018-02-13 |
2021-04-01 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
ES2958828T3
(es)
|
2018-02-15 |
2024-02-15 |
Gilead Sciences Inc |
Derivados de piridina y su uso para tratar una infección por VIH
|
|
TWI823164B
(zh)
|
2018-02-16 |
2023-11-21 |
美商基利科學股份有限公司 |
用於製備有療效化合物之方法及中間物
|
|
TWI772370B
(zh)
*
|
2018-02-26 |
2022-08-01 |
瑞士商諾華公司 |
作為胞內體類鐸（toll-like）受體抑制劑之化合物及組合物
|
|
JP7050165B2
(ja)
|
2018-02-26 |
2022-04-07 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
|
|
TW202415645A
(zh)
|
2018-03-01 |
2024-04-16 |
愛爾蘭商健生科學愛爾蘭無限公司 |
２，４－二胺基喹唑啉衍生物及其醫學用途
|
|
WO2019195181A1
(en)
|
2018-04-05 |
2019-10-10 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
|
TW202005654A
(zh)
|
2018-04-06 |
2020-02-01 |
捷克科學院有機化學與生物化學研究所 |
２，２，─環二核苷酸
|
|
TWI833744B
(zh)
|
2018-04-06 |
2024-03-01 |
捷克科學院有機化學與生物化學研究所 |
3'3'-環二核苷酸
|
|
TWI818007B
(zh)
|
2018-04-06 |
2023-10-11 |
捷克科學院有機化學與生物化學研究所 |
2'3'-環二核苷酸
|
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
|
WO2019204609A1
(en)
|
2018-04-19 |
2019-10-24 |
Gilead Sciences, Inc. |
Pd-1/pd-l1 inhibitors
|
|
US20190359645A1
(en)
|
2018-05-03 |
2019-11-28 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
|
|
JP7407740B2
(ja)
|
2018-05-18 |
2024-01-04 |
ノバルティス アーゲー |
Ｔｌｒ７／ｔｌｒ８阻害剤の結晶形態
|
|
KR102579246B1
(ko)
|
2018-07-03 |
2023-09-19 |
길리애드 사이언시즈, 인코포레이티드 |
HIV gp120을 표적화하는 항체 및 사용 방법
|
|
US11098027B2
(en)
|
2018-07-06 |
2021-08-24 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
AU2019297428C1
(en)
|
2018-07-06 |
2023-03-23 |
Gilead Sciences, Inc. |
Therapeutic heterocyclic compounds
|
|
SI3820572T1
(sl)
|
2018-07-13 |
2023-12-29 |
Gilead Sciences, Inc. |
Inhibitorji pd-1/pd-l1
|
|
AU2019307500B2
(en)
|
2018-07-16 |
2022-09-29 |
Gilead Sciences, Inc. |
Capsid inhibitors for the treatment of HIV
|
|
WO2020028097A1
(en)
|
2018-08-01 |
2020-02-06 |
Gilead Sciences, Inc. |
Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
|
|
JP2022500414A
(ja)
|
2018-09-12 |
2022-01-04 |
シルバーバック セラピューティックス インコーポレイテッド |
免疫刺激性コンジュゲートにより疾患を処置する方法および組成物
|
|
US11179397B2
(en)
|
2018-10-03 |
2021-11-23 |
Gilead Sciences, Inc. |
Imidazopyrimidine derivatives
|
|
AU2019366355B2
(en)
|
2018-10-24 |
2022-10-13 |
Gilead Sciences, Inc. |
PD-1/PD-L1 inhibitors
|
|
WO2020092528A1
(en)
|
2018-10-31 |
2020-05-07 |
Gilead Sciences, Inc. |
Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
|
|
DK3873903T3
(da)
|
2018-10-31 |
2024-04-02 |
Gilead Sciences Inc |
Substituerede 6-azabenzimidazolforbindelser som hpk1-hæmmere
|
|
JP7287708B2
(ja)
|
2019-02-08 |
2023-06-06 |
プロジェニア インコーポレイテッド |
Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途
|
|
WO2020176505A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
WO2020176510A1
(en)
|
2019-02-25 |
2020-09-03 |
Gilead Sciences, Inc. |
Protein kinase c agonists
|
|
US20220143061A1
(en)
|
2019-03-07 |
2022-05-12 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotides and prodrugs thereof
|
|
WO2020178768A1
(en)
|
2019-03-07 |
2020-09-10 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
|
|
CA3129022C
(en)
|
2019-03-07 |
2023-08-01 |
Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. |
2'3'-cyclic dinucleotides and prodrugs thereof
|
|
CN119462659A
(zh)
|
2019-03-22 |
2025-02-18 |
吉利德科学公司 |
桥连三环氨基甲酰基吡啶酮化合物及其药学用途
|
|
TW202210480A
(zh)
|
2019-04-17 |
2022-03-16 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TWI751517B
(zh)
|
2019-04-17 |
2022-01-01 |
美商基利科學股份有限公司 |
類鐸受體調節劑之固體形式
|
|
TW202231277A
(zh)
|
2019-05-21 |
2022-08-16 |
美商基利科學股份有限公司 |
鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法
|
|
TWI826690B
(zh)
|
2019-05-23 |
2023-12-21 |
美商基利科學股份有限公司 |
經取代之烯吲哚酮化物及其用途
|
|
US20220305115A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
|
US20220249685A1
(en)
|
2019-06-19 |
2022-08-11 |
Silverback Therapeutics, Inc. |
Anti-mesothelin antibodies and immunoconjugates thereof
|
|
NZ783169A
(en)
|
2019-06-25 |
2024-12-20 |
Gilead Sciences Inc |
Flt3l-fc fusion proteins and methods of use
|
|
TWI879779B
(zh)
|
2019-06-28 |
2025-04-11 |
美商基利科學股份有限公司 |
類鐸受體調節劑化合物的製備方法
|
|
KR102922000B1
(ko)
|
2019-07-16 |
2026-02-05 |
길리애드 사이언시즈, 인코포레이티드 |
Hiv 백신, 및 이의 제조 및 사용 방법
|
|
WO2021011891A1
(en)
|
2019-07-18 |
2021-01-21 |
Gilead Sciences, Inc. |
Long-acting formulations of tenofovir alafenamide
|
|
WO2021034804A1
(en)
|
2019-08-19 |
2021-02-25 |
Gilead Sciences, Inc. |
Pharmaceutical formulations of tenofovir alafenamide
|
|
BR112022005687A2
(pt)
|
2019-09-30 |
2022-06-21 |
Gilead Sciences Inc |
Vacinas contra o hbv e métodos para tratar o hbv
|
|
CA3151322A1
(en)
|
2019-10-01 |
2021-04-08 |
Silverback Therapeutics, Inc. |
Combination therapy with immune stimulatory conjugates
|
|
AU2020365113B2
(en)
|
2019-10-18 |
2025-04-24 |
Forty Seven, LLC |
Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
|
|
US20210147568A1
(en)
|
2019-10-31 |
2021-05-20 |
Forty Seven, Inc. |
Anti-cd47 based treatment of blood cancer
|
|
TWI778443B
(zh)
|
2019-11-12 |
2022-09-21 |
美商基利科學股份有限公司 |
Mcl1抑制劑
|
|
JP2023502530A
(ja)
|
2019-11-26 |
2023-01-24 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖ予防のためのカプシド阻害剤
|
|
FI4069729T3
(fi)
|
2019-12-06 |
2025-04-01 |
Prec Biosciences Inc |
Optimoidut muokatut meganukleaasit, joilla on spesifisyys tunnistussekvenssiä varten hepatiitti b -virusgenomissa
|
|
SI4081305T1
(sl)
|
2019-12-24 |
2025-03-31 |
Carna Biosciences, Inc. |
Spojine, ki modulirajo diacilglicerol kinazo
|
|
WO2021163064A2
(en)
|
2020-02-14 |
2021-08-19 |
Jounce Therapeutics, Inc. |
Antibodies and fusion proteins that bind to ccr8 and uses thereof
|
|
JP7735291B2
(ja)
|
2020-02-21 |
2025-09-08 |
エーアールエス ファーマシューティカルズ、インコーポレイテッド |
ネクチン－４抗体コンジュゲートおよびその使用
|
|
JP7811014B2
(ja)
|
2020-03-02 |
2026-02-04 |
プロジェニア インコーポレイテッド |
病原菌外壁成分基盤の生病原体模倣ナノ粒子及びその製造方法
|
|
TWI845826B
(zh)
|
2020-03-20 |
2024-06-21 |
美商基利科學股份有限公司 |
4'-c-經取代-2-鹵基-2'-去氧腺苷核苷之前藥及其製造與使用方法
|
|
EP4143194A1
(de)
|
2020-05-01 |
2023-03-08 |
Gilead Sciences, Inc. |
Cd73-hemmende 2,4-dioxopyrimidinverbindungen
|
|
TW202208355A
(zh)
|
2020-05-04 |
2022-03-01 |
美商安進公司 |
作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法
|
|
US12252489B2
(en)
|
2020-05-04 |
2025-03-18 |
Amgen Inc. |
Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use
|
|
WO2021236944A1
(en)
|
2020-05-21 |
2021-11-25 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising bictegravir
|
|
JP7520162B2
(ja)
|
2020-06-25 |
2024-07-22 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖの治療のためのカプシド阻害剤
|
|
EP4175673A1
(de)
|
2020-07-01 |
2023-05-10 |
ARS Pharmaceuticals Inc. |
Anti-asgr1-antikörperkonjugate und verwendungen davon
|
|
EP4194010A4
(de)
|
2020-08-04 |
2025-03-26 |
Progeneer Inc. |
Konjugat aus einem funktionellen arzneimittel und einem toll-like-rezeptor-7- oder -8-agonisten mit temporär inaktivierter wirkstoffstelle und verwendung davon
|
|
JP7690221B2
(ja)
|
2020-08-04 |
2025-06-10 |
プロジェニア インコーポレイテッド |
動力学的に作用するアジュバントアンサンブル
|
|
EP4194006A4
(de)
|
2020-08-04 |
2024-12-04 |
Progeneer Inc. |
Mrna-impfstoff mit einem zur kinetischen kontrolle fähigen adjuvans
|
|
AU2021320236B2
(en)
|
2020-08-07 |
2024-10-03 |
Gilead Sciences, Inc. |
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
AU2021377614B2
(en)
|
2020-11-11 |
2025-05-15 |
Gilead Sciences, Inc. |
METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES
|
|
WO2022217022A1
(en)
|
2021-04-10 |
2022-10-13 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
|
TW202302145A
(zh)
|
2021-04-14 |
2023-01-16 |
美商基利科學股份有限公司 |
ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
|
|
US20250066490A1
(en)
|
2021-04-23 |
2025-02-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
|
EP4337223A1
(de)
|
2021-05-13 |
2024-03-20 |
Gilead Sciences, Inc. |
Kombination aus einer tlr8-modulierenden verbindung und anti-hbv-sirna-therapeutika
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
WO2022271650A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CA3222277A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
AU2022297373B2
(en)
|
2021-06-23 |
2025-04-17 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
CA3222439A1
(en)
|
2021-06-23 |
2022-12-29 |
Gilead Sciences, Inc. |
Diacylglyercol kinase modulating compounds
|
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
|
CA3234909A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
EP4440700A1
(de)
|
2021-12-03 |
2024-10-09 |
Gilead Sciences, Inc. |
Therapeutische verbindungen gegen hiv-virus-infektion
|
|
HUE072195T2
(hu)
|
2021-12-03 |
2025-10-28 |
Gilead Sciences Inc |
Terápiás vegyületek HIV-vírusfertõzésre
|
|
JP7736929B2
(ja)
|
2021-12-03 |
2025-09-09 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｈｉｖウイルス感染症のための治療化合物
|
|
WO2023107956A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Proteins binding nkg2d, cd16 and 5t4
|
|
US20250059183A1
(en)
*
|
2021-12-08 |
2025-02-20 |
Shanghai Visonpharma Co., Ltd. |
Pyridine[4,3-d]pyrimidine compound as tlr7/8 agonist
|
|
US20230220106A1
(en)
|
2021-12-08 |
2023-07-13 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
|
WO2023122615A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
JP2024546851A
(ja)
|
2021-12-22 |
2024-12-26 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
TW202346277A
(zh)
|
2022-03-17 |
2023-12-01 |
美商基利科學股份有限公司 |
Ｉｋａｒｏｓ鋅指家族降解劑及其用途
|
|
EP4499146A1
(de)
|
2022-03-24 |
2025-02-05 |
Gilead Sciences, Inc. |
Kombinationstherapie zur behandlung von trop-2-exprimierenden krebs
|
|
TWI876305B
(zh)
|
2022-04-05 |
2025-03-11 |
美商基利科學股份有限公司 |
用於治療結腸直腸癌之組合療法
|
|
TW202446773A
(zh)
|
2022-04-06 |
2024-12-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
JP2025513258A
(ja)
|
2022-04-21 |
2025-04-24 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｋｒａ ｇ１２ｄ調節化合物
|
|
TWI867601B
(zh)
|
2022-07-01 |
2024-12-21 |
美商基利科學股份有限公司 |
可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
|
|
AU2023298558A1
(en)
|
2022-07-01 |
2024-12-19 |
Gilead Sciences, Inc. |
Cd73 compounds
|
|
AU2023307100A1
(en)
|
2022-07-12 |
2025-01-02 |
Gilead Sciences, Inc. |
Hiv immunogenic polypeptides and vaccines and uses thereof
|
|
KR20250051732A
(ko)
|
2022-08-26 |
2025-04-17 |
길리애드 사이언시즈, 인코포레이티드 |
광범위 중화 항체를 위한 투여 및 일정 요법
|
|
WO2024064668A1
(en)
|
2022-09-21 |
2024-03-28 |
Gilead Sciences, Inc. |
FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
|
|
EP4598934A1
(de)
|
2022-10-04 |
2025-08-13 |
Gilead Sciences, Inc. |
4'-thionukleosid-analoga und deren pharmazeutische verwendung
|
|
AU2023409398A1
(en)
|
2022-12-22 |
2025-06-05 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
EP4695260A1
(de)
|
2023-04-11 |
2026-02-18 |
Gilead Sciences, Inc. |
Kras-modulierende verbindungen
|
|
AU2024259111A1
(en)
|
2023-04-19 |
2025-10-16 |
Gilead Sciences, Inc. |
Dosing regimen of capsid inhibitor
|
|
WO2024220917A1
(en)
|
2023-04-21 |
2024-10-24 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
WO2024249573A1
(en)
|
2023-05-31 |
2024-12-05 |
Gilead Sciences, Inc. |
Solid forms of compounds useful in the treatment of hiv
|
|
TW202448483A
(zh)
|
2023-05-31 |
2024-12-16 |
美商基利科學股份有限公司 |
用於ｈｉｖ之治療性化合物
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
CN121568935A
(zh)
|
2023-07-26 |
2026-02-24 |
吉利德科学公司 |
Parp7抑制剂
|
|
TW202519517A
(zh)
|
2023-07-26 |
2025-05-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
AU2023460182A1
(en)
|
2023-07-28 |
2026-02-05 |
Gilead Sciences, Inc. |
Weekly regimen of lenacapavir for the treatment and prevention of hiv
|
|
WO2025042394A1
(en)
|
2023-08-23 |
2025-02-27 |
Gilead Sciences, Inc. |
Dosing regimen of hiv capsid inhibitor
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
WO2025054347A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
US20250115680A1
(en)
|
2023-09-26 |
2025-04-10 |
Profoundbio Us Co. |
Ptk7 binding agents, conjugates thereof and methods of using the same
|
|
WO2025080850A1
(en)
|
2023-10-11 |
2025-04-17 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
TW202530227A
(zh)
|
2023-10-11 |
2025-08-01 |
美商基利科學股份有限公司 |
橋聯三環胺甲醯基吡啶酮化合物及其用途
|
|
AU2024357911A1
(en)
|
2023-10-11 |
2026-03-26 |
Gilead Sciences, Inc. |
Bridged tricyclic carbamoylpyridone compounds and uses thereof
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250230168A1
(en)
|
2023-12-22 |
2025-07-17 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025137245A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
TW202547866A
(zh)
|
2024-01-10 |
2025-12-16 |
丹麥商珍美寶股份有限公司 |
Ｓｌｉｔｒｋ６結合劑、其共軛物及使用彼之方法
|
|
US20250381289A1
(en)
|
2024-02-29 |
2025-12-18 |
Genmab A/S |
Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
|
|
US20250296932A1
(en)
|
2024-03-01 |
2025-09-25 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|
|
WO2025184609A1
(en)
|
2024-03-01 |
2025-09-04 |
Gilead Sciences, Inc. |
Antiviral compounds
|
|
US20250289822A1
(en)
|
2024-03-01 |
2025-09-18 |
Gilead Sciences, Inc. |
Solid forms of hiv integrase inhibitors
|
|
WO2025240246A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
WO2025240243A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus
|
|
WO2025240242A1
(en)
|
2024-05-13 |
2025-11-20 |
Gilead Sciences, Inc. |
Combination therapies with ribavirin
|
|
US20250345390A1
(en)
|
2024-05-13 |
2025-11-13 |
Gilead Sciences, Inc. |
Combination therapies
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20260007683A1
(en)
|
2024-06-14 |
2026-01-08 |
Gilead Sciences, Inc. |
Pharmaceutical compositions comprising hiv integrase inhibitors
|
|
WO2026039365A1
(en)
|
2024-08-12 |
2026-02-19 |
Gilead Sciences, Inc. |
Kras modulating compounds
|